Clinical trials: in Bosnia and Herzegovina
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of…
- Trial name
- CONFIRM (NCT00451451)
- Testing
- BG00012, Glatiramer Acetate
- Where
- 195 sites in United States, Belarus and 26 more
- Volunteers
- 1,417 people
- Sponsor
- Biogen
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate…
- Trial name
- NCT01235507
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Bosnia and Herzegovina
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms…
- Trial name
- IES (NCT00038467)
- Testing
- Tamoxifen, Exemestane
- Where
- 377 sites in United States, Argentina and 35 more
- Volunteers
- 4,740 people
- Sponsor
- Pfizer
Relapsing-Remitting Multiple Sclerosis
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- GLOW (NCT01578785)
- Testing
- Glatiramer Acetate
- Where
- 169 sites in United States, Albania and 17 more
- Volunteers
- 178 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Breast Cancer
Docetaxel in Breast Cancer
Primary objective : To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer…
- Trial name
- NCT00312208
- Testing
- docetaxel, doxorubicin, cyclophosphamide, Docetaxel,doxorubicin, cyclophosphamide
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 3,299 people
- Sponsor
- Sanofi
Breast Cancer
A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer
This 2 arm study compared the efficacy and safety of label dose of capecitabine (Xeloda®) to that of a lower dose of Xeloda® plus docetaxel (Taxotere®) in patients with locally advanced or metastatic breast cancer after failure…
- Trial name
- NCT00077857
- Testing
- capecitabine (Xeloda®), docetaxel (Taxotere®)
- Where
- 94 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 470 people
- Sponsor
- Hoffmann-La Roche
Smoking Cessation, Depression
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not…
- Trial name
- NCT01078298
- Testing
- varenicline
- Where
- 41 sites in United States, Bosnia and Herzegovina and 6 more
- Volunteers
- 525 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis.
- Trial name
- NCT00853385
- Testing
- CP 690,550, CP-690,550, Biologic TNFi
- Where
- 125 sites in United States, Australia and 19 more
- Volunteers
- 717 people
- Sponsor
- Pfizer
Fungemia, Neutropenia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
The purpose of this study is to gather information on the use of anidulafungin for the treatment of Candida infection in patients with an abnormal immune system.
- Conditions
- Fungemia, Neutropenia, Candidiasis
- Trial name
- NCT00806351
- Testing
- Active Anidulafungin, Active Caspofungin
- Where
- 10 sites in Bosnia and Herzegovina, France and 4 more
- Volunteers
- 21 people
- Sponsor
- Pfizer
Cancer of Cervix
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant…
- Trial name
- NCT00191100
- Testing
- Gemcitabine, Cisplatin, Brachytherapy
- Where
- 7 sites in Argentina, Bosnia and Herzegovina and 5 more
- Volunteers
- 515 people
- Sponsor
- Eli Lilly and Company